Spectinomycin


Concise Prescribing Info
Indications/Uses
Gonorrhoea.
Dosage/Direction for Use
Adult : IM 2 g as a single dose. Max: 4 g, admin in 2 different inj sites.
Dosage Details
Intramuscular
Gonorrhoea
Adult: 2 g as a single dose. In cases whereby antibiotic resistance is prevalent, 4 g (10 mL) may be given but divided as two 5 mL inj, admin to 2 different inj sites.
Child: Beyond newborn period and <45 kg: 40 mg/kg as a single dose. Max: 2 g.
Reconstitution
Add 3.2 mL of sterile water for inj to the vial containing 2 g to make a 400 mg/mL susp (as HCl). Shake the vial vigorously after adding the diluent and prior to withdrawing the dose.
Contraindications
Hypersensitivity.
Special Precautions
Ineffective in the treatment of syphilis and may mask or delay symptoms of incubating syphilis. Pregnancy and lactation.
Adverse Reactions
Nausea, dizziness, fever and chills, insomnia, urticaria, mild to moderate pain after IM inj, alterations in kidney and liver function, decrease in Hb and haematocrit. Rarely, anaphylaxis or anaphylactiod reactions.
IM/Parenteral: B
MonitoringParameters
Perform serologic test for syphilis at the time of gonorrhoea diagnosis and 3 mth later.
Drug Interactions
May result in lithium toxicity when used concurrently. May increase or prolong the neuromuscular blocking effect of atracurium.
Action
Description: Spectinomycin binds to 30S subunit of the bacterial ribosome, thus inhibiting protein synthesis. It has modest activity against a wide range of gm+ve and gm-ve organisms, though anaerobic organisms are mostly resistant.
Pharmacokinetics:
Absorption: Rapidly absorbed after IM inj. Time to peak plasma concentration: 1 hr (2-g dose).
Distribution: Poorly distributed into saliva. Not significantly bound to plasma proteins.
Excretion: Via urine as active metabolites. Plasma half-life: Approx 1-3 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 20-25°C. Reconstituted soln should be used w/in 24 hr after preparation.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Spectinomycin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Trobicin
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in